Safety, immunogenicity, and efficacy of an alphavirus replicon-based swine influenza virus hemagglutinin vaccine

Vaccine

Volumn 30, Issue 11, 2012, Pages 1944-1950

  Vander Veen, Ryan L ^a,b   Loynachan, Alan T ^c   Mogler, Mark A ^a,b   Russell, Brandon J ^b   Harris, D L Hank ^a,b   Kamrud, Kurt I ^a,b  

^a Harrisvaccines Inc   (United States)

^b IOWA STATE UNIVERSITY   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Alphavirus replicon; Hemagglutinin (HA); Safety; Swine; Swine influenza virus (SIV); Vaccine

Indexed keywords

ALPHAVIRUS REPLICON VECTOR; GAMMA INTERFERON; INFLUENZA VIRUS HEMAGGLUTININ; SWINE INFLUENZA VACCINE; UNCLASSIFIED DRUG; VIRUS VECTOR;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMORAL IMMUNITY; IMMUNOGENICITY; INFLUENZA VACCINATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRUS SHEDDING; VIRUS VIRULENCE;

ALPHAVIRUS; ANIMALS; ANTIBODIES, VIRAL; ANTIBODY FORMATION; CYTOPATHOGENIC EFFECT, VIRAL; FEMALE; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; INFLUENZA VACCINES; INTERFERON-GAMMA; MALE; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE; ORTHOMYXOVIRIDAE INFECTIONS; REPLICON; SWINE; VIRULENCE; VIRUS SHEDDING;

EID: 84857195700     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.01.030     Document Type: Article

References (43)

1. Myers K.P., Olsen C.W., Gray G.C. Cases of swine influenza in humans: a review of the literature. Clin Infect Dis 2007, 44(8):1084-1088.
2. Shinde V., Bridges C.B., Uyeki T.M., Shu B., Balish A., Xu X., et al. Triple-reassortant swine influenza A (H1) in humans in the United States, 2005-2009. N Engl J Med 2009, 36:2616-2625.
3. Vincent A., Swenson S., Lager K., Gauger P., Loiacono C., Zhang Y. Characterization of an influenza A virus isolated from pigs during an outbreak of respiratory disease in swine and people during a county fair in the United States. Vet Microbiol 2009, 137:51-59.
4. Garten R.J., Davis C.T., Russell C.A., Shu B., Lindstrom S., Balish A., et al. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 2009, 325:197-201.
5. Vander Veen R., Kamrud K., Mogler M., Loynachan A.T., McVicker J., Berglund P., et al. Rapid development of an efficacious swine vaccine for novel H1N1. PLoS Curr 2009, 1:RRN1123.
6. Easterday B.C., Van Reeth K. Swine influenza 2007, 227-290. ISU Press, Ames, Iowa USA. 8th ed. B.E. Straw, S. D'Allaire, W.L. Mengling (Eds.).
7. Shope R.E. Swine influenza: III. Filtration experiments and etiology. J Exp Med 1931, 54(3):373-385.
8. Webby R.J., Swenson S.L., Krauss S.L., Gerrish P.J., Goyal S.M., Webster R.G. Evolution of swine H3N2 influenza viruses in the United States. J Virol 2000, 74(18):8243-8251.
9. Zhou N.N., Senne D.A., Landgraf J.S., Swenson S.L., Erickson G., Rossow K., et al. Genetic reassortment of avian, swine, and human influenza A viruses in American pigs. J Virol 1999, 73(10):8851-8856.
10. Vincent A, Ma W, Lager K, Janke B, Richt JA. Swine influenza viruses: a North American perspective. In: Maramorosch K, Shatkin AJ, Murphy FA. Burlington: Academic Press. Adv Virus Res 2008:127-54.
11. Karasin A.I., Carman S., Olsen C.W. Identification of human H1N2 and human-swine reassortant H1N2 and H1N1 influenza A viruses among pigs in Ontario, Canada (2003 to 2005). J Clin Microbiol 2006, 44(3):1123-1126.
12. Webby R.J., Rossow K., Erickson G., Sims Y., Webster R. Multiple lineages of antigenically and genetically diverse influenza A virus co-circulate in the United States swine population. Virus Res 2004, 103(1-2):67-73.
13. Richt J.A., Lager K.M., Janke B.H., Woods R.D., Webster R.G., Webby R.J. Pathogenic and antigenic properties of phylogenetically distinct reassortant H3N2 swine influenza viruses cocirculating in the United States. J Clin Microbiol 2003, 41(7):3198-3205.
14. Choi Y.K., Goyal S.M., Joo H.S. Prevalence of swine influenza virus subtypes on swine farms in the United States. Arch Virol 2002, 147(6):1209-1220.
15. Vincent A.L., Ma W., Lager K.M., Gramer M.R., Richt J.A., Janke B.H. Characterization of a newly emerged genetic cluster of H1N1 and H1N2 swine influenza virus in the United States. Virus Genes 2009, 39(2):176-185.
16. Gramer M. Swine influenza virus: epidemiology, diagnostics, and research updates. Am Assoc Swine Vet 2009, 471-474.
17. Gramer M. Emergence of reassortant influenza viruses: academic folly or clinically relevant?. Allen D Leman Swine Conference 2005, 95-96.
18. Hooper J.W., Ferro A.M., Golden J.W., Silvera P., Dudek J., Alterson K., et al. Molecular smallpox vaccine delivered by alphavirus replicons elicits protective immunity in mice and non-human primates. Vaccine 2009, 28(2):494-511.
19. Strauss J.H., Strauss E.G. The alphaviruses: gene expression, replication, and evolution. Microbiol Rev 1994, 58(3):491-562.
20. Rayner J.O., Dryga S.A., Kamrud K.I. Alphavirus vectors and vaccination. Rev Med Virol 2002, 12(5):279-296.
21. Pushko P., Parker M., Ludwig G.V., Davis N.L., Johnston R.E., Smith J.F. Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo. Virology 1997, 239(2):389-401.
22. Kamrud K.I., Coffield V.M., Owens G., Goodman C., Alterson K., Custer M., et al. In vitro and in vivo characterization of microRNA-targeted alphavirus replicon and helper RNAs. J Virol 2010, 84(15):7713-7725.
23. Geigenmuller-Gnirke U., Weiss B., Wright R., Schlesinger S. Complementation between Sindbis viral RNAs produces infectious particles with a bipartitie genome. Proc Natl Acad Sci U S A 1991, 88(8):3253-3257.
24. Berglund P., Sjoberg M., Garoff H., Atkins G.J., Sheahan B.J., Liljestrom P. Semliki Forest virus expression system: production of conditionally infectious recombinant particles. Biotechnology (NY) 1993, 11(8):916-920.
25. Smerdou C., Liljestrom P. Two-helper RNA system for production of recombinant Semliki forest virus particles. J Virol 1999, 73(2):1092-1098.
26. Kamrud K.I., Alterson K., Custer M., Dudek J., Goodman C., Owens G., et al. Development and characterization of promotorless helper RNAs for the production of alphavirus replicon particle. J Gen Virol 2010, 91(7):1723-1727.
27. Bernstein D.I., Reap E.I., Katen K., Watson A., Smith K., Norberg P., et al. Randomized, double-blind, phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers. Vaccine 2009, 28(2):484-493.
28. Hubby B., Talarico T., Maughan M., Reap E.A., Berglund P., Kamrud K.I., et al. Development and preclinical evaluation of an alphavirus replicon vaccine for influenza. Vaccine 2007, 25(48):8180-8189.
29. Erdman M.M., Kamrud K.I., Harris D.L., Smith J. Alphavirus replicon particle vaccines developed for use in humans induce high levels of antibodies to influenza virus hemagglutinin in swine: proof of concept. Vaccine 2010, 28(3):594-596.
30. Bosworth B., Erdman M.M., Stine D.L., Harris I., Irwin C., Jens M., et al. Replicon particle vaccine protects swine against influenza. Comp Immunol Microbiol Infect Dis 2010, 33(6):e99-e103.
31. Halbur P.G., Paul P.S., Frey M.L., Landgraf J., Eernisse K., Meng X.J., et al. Comparison of the pathogenicity of two US porcine reproductive and respiratory syndrome virus isolates with that of the Lelystad virus. Vet Pathol 1995, 32(6):648-660.
32. Kamrud K.I., Custer M., Dudek J.M., Owens G., Alterson K.D., Lee J.S., et al. Alphavirus replicon approach to promoterless analysis of IRES elements. Virology 2007, 360(2):376-387.
33. Zuckermann F.A., Husmann R.J., Schwartz R., Brandt J., Mateu de Antonio E., Martin S. Interleukin-12 enhances the virus-specific interferon gamma response of pigs to an inactivated pseudorabies virus vaccine. Vet Immunol Immunopathol 1998, 63(1-2):57-67.
34. Reed L.J., Muench H. A simple method of estimating fifty percent endpoint. Am J Hyg 1938, 27(3):493-497.
35. Reap E.A., Morris J., Dryga S.A., Maughan M., Talarico T., Esch R.E., et al. Development and preclinical evaluation of an alphavirus replicon particle vaccine for cytomegalovirus. Vaccine 2007, 25(42):7441-7449.
36. Kowalski J., Adkins K., Gangolli S., Ren J., Arendt H., DeStefano J., et al. Evaluation of neurovirulence and biodistribution of Venezuelan equine encephalitis replicon particles expressing herpes simplex virus type 2 glycoprotein D. Vaccine 2007, 25(12):2296-2305.
37. Altman-Hamamdzic S., Groseclose C., Ma J.X., Hamamdzic D., Vrindavanam N.S., Middaugh L.D., et al. Expression of beta-galactosidase in mouse brain: utilization of a novel nonreplicative Sindbis virus vector as a neuronal gene delivery system. Gene Ther 1997, 4(8):815-822.
38. Lundstrom K., Richards J.G., Pink J.R., Jenck F. Efficient in vivo expression of a reporter gene in a rat brain after injection of recombinant replication-deficient Semliki Forest virus. Gen Ther Mol Biol 1999, 3:15-23.
39. Morris-Downes M.M., Phenix K.V., Smyth J., Sheahan B.J., Lilegvist S., Mooney D.A., et al. Semliki Forest virus-based vaccines: persistence, distribution and pathological analysis in two animal systems. Vaccine 2001, 19(15-16):1978-1988.
40. Pittman P.R., Makuch R.S., Mangiafico J.A., Cannon T.L., Gibbs P.H., Peters C.J. Long-term duration of detectable neutralizing antibodies after administration of live-attenuated VEE vaccine and following booster vaccination with inactivated VEE vaccine. Vaccine 1996, 14(4):337-343.
41. Schultz-Cherry S., Dybing J.K., Davis N.L., Williamson C., Suarez D.L., Johnston R., et al. Influenza virus (A/HK/156/97) hemagglutinin expressed by an alphavirus replicon system protects chickens against lethal infection with Hong Kong-origin H5N1 viruses. Virology 2000, 278(1):55-59.
42. Ciacci-Zanella J.R., Vincent A.L., Prickett J.R., Zimmerman S.M., Zimmerman J.J. Detection of anti-influenza A nucleoprotein antibodies in pigs using a commercial influenza epitope-blocking enzyme-linked immunosorbent assay developed for avian species. J Vet Diagn Invest 2010, 22(1):3-9.
43. Morse M.A., Hobeika A.C., Osada T., Berglund P., Hubby B., Negri S., et al. An alphavirus vector overcomes the presence of neutralizing antibodies and elevated numbers of Tregs to induce immune responses in humans with advanced cancer. J Clin Invest 2010, 120(9):3234-3241.